ARV-825 | BRD4 PROTAC Degrader | AmBeed-信号通路专用抑制剂

ARV-825 {[allProObj[0].p_purity_real_show]}

货号：A370626

ARV-825是一种PROTAC，连接Cereblon和BRD4的配体，结合BRD4的BD1和BD2，Kd值分别为90 nM和28 nM。

ARV-825 化学结构
CAS号：1818885-28-7

ARV-825 3D分子结构
CAS号：1818885-28-7

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

表观遗传阅读框亚型比较

产品名称	BET ↓ ↑	bromodomain ↓ ↑	BRPF ↓ ↑	CBP/beta-catenin ↓ ↑	p300/CBP ↓ ↑	其他靶点	纯度
MS436	++ BRD4 (1), Ki: <0.085 μM BRD4 (2), Ki: 0.34 μM						99%+
CPI-203	+++ BRD4, IC50: 37 nM						98+%
GSK1324726A	+++ BRD4, IC50: 22 nM BRD2, IC50: 31 nM						99%+
PFI-1	++ BRD4, IC50: 0.22 μM BRD2, IC50: 98 nM						98%
Apabetalone	+ BD2, IC50: 0.51 μM						99%
(+)-JQ1	+++ BRD4 (1), IC50: 77 nM BRD4 (2), IC50: 33 nM						98%
I-BET151	+ BRD3, IC50: 0.25 μM BRD4, IC50: 0.5 μM						98%
Molibresib	+++ BET proteins, IC50: 35 nM						99%+
I-BRD9	+++ BRD4, pIC50: 5.3 BRD9, pIC50: 7.3						99%+
BI-7273	++++ BRD7, IC50: 117 nM BRD9, IC50: 19 nM						97%
Pelabresib	+++ BRD4-BD1, IC50: 39 nM						98%
ARV-825	+++ BRD4 BD1, Kd: 90 nM BRD4 BD2, Kd: 28 nM						99%+
Birabresib							99%+
BI 2536	+++ BRD4, Kd: 37 nM					c-Myc	99%+
Bromosporine	++ BRD2, IC50: 0.29 μM BRD9, IC50: 0.122 μM	++++ CECR2, IC50: 17 nM					99%+
XMD8-92	++ BRD4 (1), Kd: 170 nM						99%+
Mivebresib	✔						99%+
BI-9564	++++ BRD9, Kd: 5.9 nM BRD7, Kd: 73 nM	++ CECR2, Kd: 77 nM					98%
AZD5153 6-Hydroxy-2-naphthoic acid	++++ FL-BRD4, IC50: 5 nM						99%+
PLX51107	++++ BRD3 BD1, Kd: 2.1 nM BRD4 BD2, Kd: 1.7 nM						99%+
FL-411	+ BRD4(1), IC50: 0.43 μM						99%+
ABBV-744	✔						99%+
dBET6	++++ BRD4, IC50: 14 nM						99%+
dBET1	++++ BRD4, IC50: 20 nM						99%+
MZ1	++++ Brd2(BD2), Kd: 62 nM Brd3(BD2), Kd: 13 nM						99%+
dBET57	+ BRD4_BD1, DC50: 500 nM						99%+
SF2523	+ BRD4, IC50: 241 nM					DNA-PK	99%+
INCB054329	++++ BRD4-BD1, IC50: 119 nM BRD3-BD1, IC50: 9 nM						99%
INCB-057643	✔						99%+
(E/Z)-ZL0420	+++ BRD4 BD1, IC50: 27 nM BRD4 BD2, IC50: 32 nM						99%+
BMS-986158	✔						99%
BRD4 Inhibitor-10	++++ BRD4-BD1, IC50: 5 nM BRD4-BD2, IC50: 41 nM						97%
A1874	✔						99%+
Y06036	++ BRD4 (1), Kd: 82 nM						99%+
Alobresib	✔					NF-κB	95%
ODM-207	✔						98%
GSK778	+++ BRD2-BD1, IC50: 75nM BRD4-BD1, IC50: 143 nM						97%
SRX3207	+ BRD42, IC50: 3070 nM BRD41, IC50: 3070 nM					Syk	98%
GSK046	+++ BRD4_BD2, IC50: 214 nM BRD3_BD2, IC50: 98 nM						98%
GSK620	✔						97%
Trotabresib	✔						99%
NHWD-870	✔						98%
CFT8634	++++ BRD9, DC50: 3 nM						98%
GSK2801		++ BAZ2A, Kd: 257 nM BAZ2B, Kd: 136 nM					99%+
KG-501		✔					99%+
UNC 669		+ L3MBTL3, IC50: 35 μM L3MBTL4, IC50: 6 μM					99%
PFI-3		+++ SMARCA2A, Kd: 72 nM SMARCA4, Kd: 55 nM					99%+
UNC1215		+++ L3MBTL3, IC50: 120 nM L3MBTL3- D274A, IC50: 3.5 μM					99%+
EED226		++ PRC2, Kd: 114 nM EED, Kd: 82 nM					99%+
BRD9539		✔					98%
UNC926		+ L3MBTL1, Kd: 3.9 μM					99%
666-15		++ CREB, IC50: 81 nM					99%+
UNC6852		+ EED, IC50: 247 nM					98%
BAZ1A-IN-1		+ BAZ1A, Kd: 0.52 μM					99%+
PFI-4			++ BRPF1, IC50: 80 nM BRPF2, IC50: 7.9 μM				99%+
OF-1			++ BRPF1B, Kd: 100 nM BRPF2, Kd: 500 nM				99%+
GSK-5959			++ BRPF2, pIC50: 5.2 BRPF3, pIC50: 7.1				99%
GSK6853			++++ BRPF1, pIC50: 8.1				99%+
NI-42			++++ BRPF1, IC50: 48 nM BRPF3, IC50: 260 nM				99%+
E-7386				+++ CBP/beta-catenin, IC50: 0.0484 μM			99%
I-CBP112					++ p300, Kd: 167 nM CBP, Kd: 151 nM		98+%
Histone Acetyltransferase Inhibitor II					+ p300, IC50: 5 μM		98%
C646					+ p300/CBP, Ki: 400 nM		99%+
Anacardic Acid					+ p300/CBP, IC50: 8.5 μM PCAF, IC50: 5 μM		99%+
SGC-CBP30					++++ CREBBP, IC50: 21 nM EP300, IC50: 38 nM		99%+
Nordihydroguaiaretic acid					✔	HER2,IGF-1R	99%+
Curcumin					+ p300, IC50: ~25 μM	Ferroptosis,Nrf2,NF-κB	98%
CPI-637					+++ CBP, IC50: 0.03 μM EP300, IC50: 0.051 μM		99%+
Foscenvivint					✔	β-catenin	99%+
A-485					++ p300 HAT, IC50: 0.06 μM		99%+
GNE-781	+ BRD4(1), IC50: 5100 nM				++++ CBP, IC50: 0.94 nM		99%
NEO2734	+++ BET, IC50: <30 nM				+++ p300/CBP, IC50: <30 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

ARV-825 生物活性

靶点

BET

BRD4 BD1, Kd:90 nM

BRD4 BD2, Kd:28 nM

描述

ARV-825 is a PROTAC targeting on BRD4, consisting of a BRD4-ligand JQ-1 linked to a cereblon E3 ligase ligand Pomalidomide, with K_ds values of 90nM and 28nM for affinity to BD1 and BD2. ARV-825 led to a fast and efficient degradation of BRD4 at concentration ranging in 1-300nM in Namalwa and CA-46 cells and a dose-dependent degradation of BRD4 post 1-24h in Namalwa and Ramos cells exposure to 100nM ARV-825. Also, it led to a more significant c-MYC suppression than JQ1 or OTX015 by depletion of BRD4 by ARV-825 at different concentration (0.1, 0.3 and 1μM) or time point (2-24h), as well as a longer lasting effect after washout (6, 24h). Consistent with this downregulation of c-MYC, ARV-825 achieved a superior effect on suppression of BL cell proliferation and apoptosis induction compared with JQ1 or OTX015, including Namalwa, CA-46, Ramos and DAUDI cell lines^[1].

ARV-825 细胞实验

Cell Line MDA-MB-231 MDA-MB-231R MDA-MB-231 HCC1937 SKO-007(J3) LPS141 MLS402 SUP-T1 cells KOPT-K1 cells SET2 cells GL261 cells B16 cells DC2.4 cells SKO-007(J3) GL261 cells LN229 cells U251 cells U87 cells UKE1 cells U251 cells BT549 SKOV3 OVCAR3 Jurkat CCRF-CEM Molt4 6 T-CEM	Concentration	Treated Time	Description	References
MDA-MB-231	0.4 µM	12, 24, or 48 hours	ARV-825 significantly reduced the expression levels of BET proteins BRD4 and BRD2, although the reduction of BRD4 was milder in the resistant cells.	J Exp Clin Cancer Res. 2019 Aug 30;38(1):383.
MDA-MB-231R	0.4 µM	12, 24, or 48 hours	ARV-825 significantly reduced the expression levels of BET proteins BRD4 and BRD2, although the reduction of BRD4 was milder in the resistant cells.	J Exp Clin Cancer Res. 2019 Aug 30;38(1):383.
MDA-MB-231	0.5 µM	24 hours	ARV-825 inhibits mammosphere formation in MDA-MB-231 cells and reduces CD44+/CD24- and ALDH expressing subpopulations.	Cell Commun Signal. 2023 Nov 3;21(1):315.
HCC1937	0.1 µM	24 hours	ARV-825 inhibits mammosphere formation in HCC1937 cells and reduces ALDH expressing subpopulations.	Cell Commun Signal. 2023 Nov 3;21(1):315.
SKO-007(J3)	0.2 µM	24 hours	ARV-825 significantly downregulated IRF4 and cMYC expression and upregulated MICA expression.	J Hematol Oncol. 2016 Dec 1;9(1):134.
LPS141	200 nM	24 hours	To evaluate the anti-proliferative effect of ARV-825 on LPS141 cells, results showed that ARV-825 significantly inhibited cell proliferation.	Nat Commun. 2019 Mar 22;10(1):1353.
MLS402	200 nM	24 hours	To evaluate the anti-proliferative effect of ARV-825 on MLS402 cells, results showed that ARV-825 significantly inhibited cell proliferation.	Nat Commun. 2019 Mar 22;10(1):1353.
SUP-T1 cells	20 nM	24 hours	ARV-825 treatment resulted in downregulation of MYC and CD44 expression, along with decreased protein levels of NOTCH1, MYC, and CD44.	Leukemia. 2022 May;36(5):1261-1273.
KOPT-K1 cells	50 nM	24 hours	ARV-825 treatment led to significant downregulation of CD44 and CD44v8-10 mRNA and increased intracellular ROS levels.	Leukemia. 2022 May;36(5):1261-1273.
SET2 cells	1.0 µM	24 hours	To compare the effects of ARV-825 and OTX015 on the levels of BRD4 and BRD2 in sAML SET2 cells, the results showed that ARV-825 significantly reduced the levels of BRD4 and BRD2.	Leukemia. 2017 Sep;31(9):1951-1961.
GL261 cells	0.0625 μg/ml	24 hours	To evaluate the cytotoxicity of cRGD-P/ARV-DOX on GL261 cells, the results showed that cRGD-P/ARV-DOX had greater cytotoxicity to GL261 cells at 24 h and 48 h.	Mater Today Bio. 2022 Sep 12;16:100423.
B16 cells	200 ng/mL	24 hours	ARV-825 significantly reduced the viability of B16 cells, and MNC@Ca/MnCO3/ARV nanoparticles showed stronger cytotoxicity, significantly inducing ferroptosis in B16 cells.	Mater Today Bio. 2025 Jan 24;31:101523.
DC2.4 cells	200 ng/mL	24 hours	ARV-825 showed no significant toxicity to DC2.4 cells, indicating its safety for normal immune cells.	Mater Today Bio. 2025 Jan 24;31:101523.
SKO-007(J3)	0.2 µM	48 hours	ARV-825 significantly inhibited IRF4 and cMYC mRNA expression and upregulated MICA mRNA expression.	J Hematol Oncol. 2016 Dec 1;9(1):134.
GL261 cells	100 ng/mL	48 hours	To evaluate the effects of ARV-825 on cell proliferation, cell cycle, and apoptosis, results showed that ARV-825 significantly inhibited cell proliferation, induced apoptosis, and blocked the cell cycle.	Adv Sci (Weinh). 2024 Dec;11(48):e2409753.
LN229 cells	100 ng/mL	48 hours	To evaluate the effects of ARV-825 on cell proliferation, cell cycle, and apoptosis, results showed that ARV-825 significantly inhibited cell proliferation, induced apoptosis, and blocked the cell cycle.	Adv Sci (Weinh). 2024 Dec;11(48):e2409753.
U251 cells	100 ng/mL	48 hours	To evaluate the effects of ARV-825 on cell proliferation, cell cycle, and apoptosis, results showed that ARV-825 significantly inhibited cell proliferation, induced apoptosis, and blocked the cell cycle.	Adv Sci (Weinh). 2024 Dec;11(48):e2409753.
U87 cells	100 ng/mL	48 hours	To evaluate the effects of ARV-825 on cell proliferation, cell cycle, and apoptosis, results showed that ARV-825 significantly inhibited cell proliferation, induced apoptosis, and blocked the cell cycle.	Adv Sci (Weinh). 2024 Dec;11(48):e2409753.
UKE1 cells	256 ± 12.45 nM	48 hours	To compare the effects of ARV-825 and OTX015 on apoptosis in UKE1 cells, the results showed that ARV-825 induced significant apoptosis at a concentration of 256 ± 12.45 nM.	Leukemia. 2017 Sep;31(9):1951-1961.
U251 cells	0.125 μg/ml	48 hours	To evaluate the cytotoxicity of cRGD-P/ARV-DOX on U251 cells, the results showed that cRGD-P/ARV-DOX had better synergetic anti-cancer effects at 48 h.	Mater Today Bio. 2022 Sep 12;16:100423.
BT549	0.2, 0.4, and 1 µM	48 or 96 hours	ARV-825 exhibited significant antiproliferative activity in BT549 cells.	J Exp Clin Cancer Res. 2019 Aug 30;38(1):383.
SKOV3	0.2, 0.4, and 1 µM	48 or 96 hours	ARV-825 exhibited significant antiproliferative activity in SKOV3 cells.	J Exp Clin Cancer Res. 2019 Aug 30;38(1):383.
OVCAR3	0.2, 0.4, and 1 µM	48 or 96 hours	ARV-825 exhibited significant antiproliferative activity in OVCAR3 cells.	J Exp Clin Cancer Res. 2019 Aug 30;38(1):383.
Jurkat	1 µM	7 days	ARV-825 significantly inhibited the proliferation of Jurkat cells and suppressed cell growth by inducing cell cycle arrest and apoptosis.	Cancer Cell Int. 2021 Apr 22;21(1):230.
CCRF-CEM	1 µM	7 days	ARV-825 significantly inhibited the proliferation of CCRF-CEM cells and suppressed cell growth by inducing cell cycle arrest and apoptosis.	Cancer Cell Int. 2021 Apr 22;21(1):230.
Molt4	1 µM	7 days	ARV-825 significantly inhibited the proliferation of Molt4 cells and suppressed cell growth by inducing cell cycle arrest and apoptosis.	Cancer Cell Int. 2021 Apr 22;21(1):230.
6 T-CEM	1 µM	7 days	ARV-825 significantly inhibited the proliferation of 6 T-CEM cells and suppressed cell growth by inducing cell cycle arrest and apoptosis.	Cancer Cell Int. 2021 Apr 22;21(1):230.

Cell Line

Concentration

Treated Time

Description

References

MDA-MB-231

0.4 µM

12, 24, or 48 hours

ARV-825 significantly reduced the expression levels of BET proteins BRD4 and BRD2, although the reduction of BRD4 was milder in the resistant cells.

J Exp Clin Cancer Res. 2019 Aug 30;38(1):383.

MDA-MB-231R

0.4 µM

12, 24, or 48 hours

ARV-825 significantly reduced the expression levels of BET proteins BRD4 and BRD2, although the reduction of BRD4 was milder in the resistant cells.

J Exp Clin Cancer Res. 2019 Aug 30;38(1):383.

MDA-MB-231

0.5 µM

24 hours

ARV-825 inhibits mammosphere formation in MDA-MB-231 cells and reduces CD44+/CD24- and ALDH expressing subpopulations.

Cell Commun Signal. 2023 Nov 3;21(1):315.

HCC1937

0.1 µM

24 hours

ARV-825 inhibits mammosphere formation in HCC1937 cells and reduces ALDH expressing subpopulations.

Cell Commun Signal. 2023 Nov 3;21(1):315.

SKO-007(J3)

0.2 µM

24 hours

ARV-825 significantly downregulated IRF4 and cMYC expression and upregulated MICA expression.

J Hematol Oncol. 2016 Dec 1;9(1):134.

LPS141

200 nM

24 hours

To evaluate the anti-proliferative effect of ARV-825 on LPS141 cells, results showed that ARV-825 significantly inhibited cell proliferation.

Nat Commun. 2019 Mar 22;10(1):1353.

MLS402

200 nM

24 hours

To evaluate the anti-proliferative effect of ARV-825 on MLS402 cells, results showed that ARV-825 significantly inhibited cell proliferation.

Nat Commun. 2019 Mar 22;10(1):1353.

SUP-T1 cells

20 nM

24 hours

ARV-825 treatment resulted in downregulation of MYC and CD44 expression, along with decreased protein levels of NOTCH1, MYC, and CD44.

Leukemia. 2022 May;36(5):1261-1273.

KOPT-K1 cells

50 nM

24 hours

ARV-825 treatment led to significant downregulation of CD44 and CD44v8-10 mRNA and increased intracellular ROS levels.

Leukemia. 2022 May;36(5):1261-1273.

SET2 cells

1.0 µM

24 hours

To compare the effects of ARV-825 and OTX015 on the levels of BRD4 and BRD2 in sAML SET2 cells, the results showed that ARV-825 significantly reduced the levels of BRD4 and BRD2.

Leukemia. 2017 Sep;31(9):1951-1961.

GL261 cells

0.0625 μg/ml

24 hours

To evaluate the cytotoxicity of cRGD-P/ARV-DOX on GL261 cells, the results showed that cRGD-P/ARV-DOX had greater cytotoxicity to GL261 cells at 24 h and 48 h.

Mater Today Bio. 2022 Sep 12;16:100423.

B16 cells

200 ng/mL

24 hours

ARV-825 significantly reduced the viability of B16 cells, and MNC@Ca/MnCO3/ARV nanoparticles showed stronger cytotoxicity, significantly inducing ferroptosis in B16 cells.

Mater Today Bio. 2025 Jan 24;31:101523.

DC2.4 cells

200 ng/mL

24 hours

ARV-825 showed no significant toxicity to DC2.4 cells, indicating its safety for normal immune cells.

Mater Today Bio. 2025 Jan 24;31:101523.

SKO-007(J3)

0.2 µM

48 hours

ARV-825 significantly inhibited IRF4 and cMYC mRNA expression and upregulated MICA mRNA expression.

J Hematol Oncol. 2016 Dec 1;9(1):134.

GL261 cells

100 ng/mL

48 hours

To evaluate the effects of ARV-825 on cell proliferation, cell cycle, and apoptosis, results showed that ARV-825 significantly inhibited cell proliferation, induced apoptosis, and blocked the cell cycle.

Adv Sci (Weinh). 2024 Dec;11(48):e2409753.

LN229 cells

100 ng/mL

48 hours

Adv Sci (Weinh). 2024 Dec;11(48):e2409753.

U251 cells

100 ng/mL

48 hours

Adv Sci (Weinh). 2024 Dec;11(48):e2409753.

U87 cells

100 ng/mL

48 hours

Adv Sci (Weinh). 2024 Dec;11(48):e2409753.

UKE1 cells

256 ± 12.45 nM

48 hours

To compare the effects of ARV-825 and OTX015 on apoptosis in UKE1 cells, the results showed that ARV-825 induced significant apoptosis at a concentration of 256 ± 12.45 nM.

Leukemia. 2017 Sep;31(9):1951-1961.

U251 cells

0.125 μg/ml

48 hours

To evaluate the cytotoxicity of cRGD-P/ARV-DOX on U251 cells, the results showed that cRGD-P/ARV-DOX had better synergetic anti-cancer effects at 48 h.

Mater Today Bio. 2022 Sep 12;16:100423.

BT549

0.2, 0.4, and 1 µM

48 or 96 hours

ARV-825 exhibited significant antiproliferative activity in BT549 cells.

J Exp Clin Cancer Res. 2019 Aug 30;38(1):383.

SKOV3

0.2, 0.4, and 1 µM

48 or 96 hours

ARV-825 exhibited significant antiproliferative activity in SKOV3 cells.

J Exp Clin Cancer Res. 2019 Aug 30;38(1):383.

OVCAR3

0.2, 0.4, and 1 µM

48 or 96 hours

ARV-825 exhibited significant antiproliferative activity in OVCAR3 cells.

J Exp Clin Cancer Res. 2019 Aug 30;38(1):383.

Jurkat

1 µM

7 days

ARV-825 significantly inhibited the proliferation of Jurkat cells and suppressed cell growth by inducing cell cycle arrest and apoptosis.

Cancer Cell Int. 2021 Apr 22;21(1):230.

CCRF-CEM

1 µM

7 days

ARV-825 significantly inhibited the proliferation of CCRF-CEM cells and suppressed cell growth by inducing cell cycle arrest and apoptosis.

Cancer Cell Int. 2021 Apr 22;21(1):230.

Molt4

1 µM

7 days

ARV-825 significantly inhibited the proliferation of Molt4 cells and suppressed cell growth by inducing cell cycle arrest and apoptosis.

Cancer Cell Int. 2021 Apr 22;21(1):230.

6 T-CEM

1 µM

7 days

ARV-825 significantly inhibited the proliferation of 6 T-CEM cells and suppressed cell growth by inducing cell cycle arrest and apoptosis.

Cancer Cell Int. 2021 Apr 22;21(1):230.

ARV-825 动物实验

Species Mice Nude mice C57BL/6 mice C57BL/6 mice Balb/c Nude mice NSG mice Mice	Animal Model GL261 subcutaneous tumor model T-ALL xenograft model Melanoma model Subcutaneous glioma model TNBC tumor model LPS141 xenograft model T-ALL PDX model	Administration	Dosage	Frequency	Description	References
Mice	GL261 subcutaneous tumor model	Intravenously injected	10 mg/kg	Every two days for a total of four times	To evaluate the antitumor efficacy of ARV-825 in vivo, results showed that ARV-825 significantly inhibited tumor growth and prolonged the survival of mice.	Adv Sci (Weinh). 2024 Dec;11(48):e2409753.
Nude mice	T-ALL xenograft model	Intraperitoneal injection	10 mg/kg	Once daily for 14 days	ARV-825 significantly inhibited tumor growth in the T-ALL xenograft model and suppressed tumor proliferation by downregulating BRD4 and c-Myc protein expression.	Cancer Cell Int. 2021 Apr 22;21(1):230.
C57BL/6 mice	Melanoma model	IntratumOral injection	100 μL	Injected on days 7, 11, and 15, continued until day 22	MNC@Ca/MnCO3/ARV/anti-PD1 nanoparticles significantly inhibited melanoma growth and enhanced anti-tumor immune responses, successfully constructing an in situ tumor vaccine.	Mater Today Bio. 2025 Jan 24;31:101523.
C57BL/6 mice	Subcutaneous glioma model	Intravenous injection	2.5 mg/kg	Every three days for three consecutive times	To evaluate the anti-tumor efficacy of cRGD-P/ARV-DOX in the subcutaneous glioma model, the results showed that cRGD-P/ARV-DOX significantly inhibited tumor growth.	Mater Today Bio. 2022 Sep 12;16:100423.
Balb/c Nude mice	TNBC tumor model	Intravenous injection	3.5 mg/kg	Every other day for a total of 5 times	To evaluate the antitumor effect of ARV-MBs combined with ultrasound in the TNBC tumor model, the results showed that ARV-MBs combined with ultrasound significantly inhibited tumor growth, with a tumor inhibition rate of 81.4%.	Biomater Res. 2024 Aug 13;28:0064
NSG mice	LPS141 xenograft model	Intraperitoneal injection	5 mg/kg	Once daily, 5 days per week, continuous treatment	To evaluate the anti-tumor effect of ARV-825 on the LPS141 xenograft model, results showed that ARV-825 significantly delayed tumor growth and prolonged mouse survival.	Nat Commun. 2019 Mar 22;10(1):1353.
Mice	T-ALL PDX model	Intraperitoneal injection	5 mg/kg or 10 mg/kg	Three times a week for several weeks	ARV-825 treatment significantly reduced leukemia burden and prolonged the survival of mice.	Leukemia. 2022 May;36(5):1261-1273.

Species

Mice Nude mice C57BL/6 mice C57BL/6 mice Balb/c Nude mice NSG mice Mice

Animal Model

GL261 subcutaneous tumor model T-ALL xenograft model Melanoma model Subcutaneous glioma model TNBC tumor model LPS141 xenograft model T-ALL PDX model

Administration

Dosage

Frequency

Description

References

Mice

GL261 subcutaneous tumor model

Intravenously injected

10 mg/kg

Every two days for a total of four times

To evaluate the antitumor efficacy of ARV-825 in vivo, results showed that ARV-825 significantly inhibited tumor growth and prolonged the survival of mice.

Adv Sci (Weinh). 2024 Dec;11(48):e2409753.

Nude mice

T-ALL xenograft model

Intraperitoneal injection

10 mg/kg

Once daily for 14 days

ARV-825 significantly inhibited tumor growth in the T-ALL xenograft model and suppressed tumor proliferation by downregulating BRD4 and c-Myc protein expression.

Cancer Cell Int. 2021 Apr 22;21(1):230.

C57BL/6 mice

Melanoma model

IntratumOral injection

100 μL

Injected on days 7, 11, and 15, continued until day 22

MNC@Ca/MnCO3/ARV/anti-PD1 nanoparticles significantly inhibited melanoma growth and enhanced anti-tumor immune responses, successfully constructing an in situ tumor vaccine.

Mater Today Bio. 2025 Jan 24;31:101523.

C57BL/6 mice

Subcutaneous glioma model

Intravenous injection

2.5 mg/kg

Every three days for three consecutive times

To evaluate the anti-tumor efficacy of cRGD-P/ARV-DOX in the subcutaneous glioma model, the results showed that cRGD-P/ARV-DOX significantly inhibited tumor growth.

Mater Today Bio. 2022 Sep 12;16:100423.

Balb/c Nude mice

TNBC tumor model

Intravenous injection

3.5 mg/kg

Every other day for a total of 5 times

To evaluate the antitumor effect of ARV-MBs combined with ultrasound in the TNBC tumor model, the results showed that ARV-MBs combined with ultrasound significantly inhibited tumor growth, with a tumor inhibition rate of 81.4%.

Biomater Res. 2024 Aug 13;28:0064

NSG mice

LPS141 xenograft model

Intraperitoneal injection

5 mg/kg

Once daily, 5 days per week, continuous treatment

To evaluate the anti-tumor effect of ARV-825 on the LPS141 xenograft model, results showed that ARV-825 significantly delayed tumor growth and prolonged mouse survival.

Nat Commun. 2019 Mar 22;10(1):1353.

Mice

T-ALL PDX model

Intraperitoneal injection

5 mg/kg or 10 mg/kg

Three times a week for several weeks

ARV-825 treatment significantly reduced leukemia burden and prolonged the survival of mice.

Leukemia. 2022 May;36(5):1261-1273.

ARV-825 动物研究

Dose

Mice: 5 mg/kg^[2] (i.p.), 10 mg/kg^[3] (i.p.), 50 mg/kg^[4] (i.p.)

Administration

i.p.

ARV-825 参考文献

ARV-825 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

1.08mL

0.22mL

0.11mL

5.41mL

1.08mL

0.54mL

10.83mL

2.17mL

1.08mL

ARV-825 技术信息

CAS号	1818885-28-7
分子式	C₄₆H₄₇ClN₈O₉S
分子量	923.43
SMILES Code	CC1=NN=C2N1C(SC(C)=C3C)=C3C(C4=CC=C(Cl)C=C4)=N[C@H]2CC(NC5=CC=C(OCCOCCOCCOCCNC6=C(C(N(C7CCC(NC7=O)=O)C8=O)=O)C8=CC=C6)C=C5)=O
MDL No.	MFCD29472237

别名
运输	蓝冰
InChI Key	RWLOGRLTDKDANT-TYIYNAFKSA-N
Pubchem ID	92044400

存储条件

In solvent -20°C: 3-6个月 -80°C: 12个月

Pure form Keep in dark place, sealed in dry, 2-8°C

溶解方案

细胞实验：

DMSO: 50 mg/mL(54.15 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

ARV-825 {[allProObj[0].p_purity_real_show]}

ARV-825 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

ARV-825 质控信息

ARV-825 生物活性

ARV-825 细胞实验

ARV-825 动物实验

ARV-825 动物研究

ARV-825 参考文献

ARV-825 实验方案

ARV-825 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

ARV-825 {[allProObj[0].p_purity_real_show]}

ARV-825 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

ARV-825 质控信息

ARV-825 生物活性

ARV-825 细胞实验

ARV-825 动物实验

ARV-825 动物研究

ARV-825 参考文献

ARV-825 实验方案

ARV-825 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

ARV-825 纯度/质量文件产品仅供科研